We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC
SGMO

Delisted

SGMO was delisted on the 4th of May, 2026.

Back to rankings

103 hedge funds and large institutions have $48.4M invested in SANGAMO THERAPEUTICS INC in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more capital invested

Capital invested by funds: $31.1M → $48.4M (+$17.3M)

15.02% less ownership

Funds ownership: 41.88% → 26.86% (-15%)

20% less funds holding

Funds holding: 129 → 103 (-26)

36% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 36

63% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 40

66% less call options, than puts

Call options by funds: $525K | Put options by funds: $1.54M

Holders
103
Holders Change
-26
Holders Change %
-20.16%
% of All Funds
1.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
23
Reduced
36
Closed
40
Calls
$525K
Puts
$1.54M
Net Calls
-$1.02M
Net Calls Change
-$988K

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$1.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$532K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$199K
4
Citadel Advisors
Citadel Advisors
Florida
+$180K
5
Vontobel Holding
Vontobel Holding
Switzerland
+$177K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$5.04M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.69M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.63M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.08M
5
Goldman Sachs
Goldman Sachs
New York
-$927K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
76
JP Morgan Chase
New York
$2.78K – – –
Optiver Holding
77
Optiver Holding
Netherlands
$2.77K – – –
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$2.69K – – –
APW
79
Atlantic Private Wealth
North Carolina
$2.17K +$1.83K +2,500 New
AF
80
Advisornet Financial
Minnesota
$1.81K – – –
BLC
81
Brown, Lisle/Cummings
Rhode Island
$1.32K – – –
BL
82
BFSG LLC
California
$1.07K -$1.78K -2,429 -66%
Carson Wealth (CWM LLC)
83
Carson Wealth (CWM LLC)
Nebraska
$1K -$92 -125 -9%
PNC Financial Services Group
84
PNC Financial Services Group
Pennsylvania
$934 – – –
AF
85
Allworth Financial
California
$867 – – –
AWM
86
Activest Wealth Management
Florida
$866 – – –
CIBC Private Wealth Group
87
CIBC Private Wealth Group
Georgia
$866 – – –
SPIA
88
Steward Partners Investment Advisory
New York
$866 – – –
VWM
89
Venturi Wealth Management
Texas
$434 – – –
GRP
90
Global Retirement Partners
California
$424 – – –
S
91
Sachetta
Massachusetts
$420 +$355 +484 New
SSB
92
Sandy Spring Bank
Maryland
$347 – – –
PS
93
Planned Solutions
California
$260 +$220 +300 New
AFG
94
Albion Financial Group
Utah
$174 – – –
CAS
95
Coppell Advisory Solutions
Texas
$173 – – –
National Bank of Canada
96
National Bank of Canada
Quebec, Canada
$173 – – –
CPA
97
Capital Performance Advisors
California
$173 +$147 +200 New
BTI
98
Blue Trust Inc
Georgia
$160 +$327 +446 New
AAP
99
Arax Advisory Partners
Colorado
$123 – – –
GWSG
100
GPS Wealth Strategies Group
Colorado
$87 – – –
2 3
4
5 6

SGMO Hedge Fund Activity: Q3 2024 in Review

103 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2024, worth a combined $48.4M — up 56% from $31.1M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of SGMO and 15 opened new positions — a net loss of 25 holders — while 36 trimmed existing stakes and 23 added.

The largest buyer was Marshall Wace, adding an estimated $1.3M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.04M sold.

  • 103 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2024, down from 129 in Q2 2024.
  • Funds reported $48.4M of SANGAMO THERAPEUTICS INC stock for Q3 2024, up 56% quarter-over-quarter.
  • 15 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2024 and 40 closed out, a net change of -25 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2024 was Marshall Wace, an estimated $1.3M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2024 was Armistice Capital, an estimated $5.04M sold.

Based on aggregated 13F filings for Q3 2024.